The Risk of Pulmonary Embolism in Patients With Pemphigus: A Population-Based Large-Scale Longitudinal Study

Khalaf Kridin, Mouhammad Kridin, Kyle T Amber, Guy Shalom, Doron Comaneshter, Erez Batat, Arnon D Cohen, Khalaf Kridin, Mouhammad Kridin, Kyle T Amber, Guy Shalom, Doron Comaneshter, Erez Batat, Arnon D Cohen

Abstract

Growing evidence suggests that inflammation may pose an atypical risk factor for pulmonary embolism (PE), as it drives venous thrombosis via several pathways. The increased risk of PE in several autoimmune diseases has lent weight to this concept. However, the relative risk of PE among patients with pemphigus has not yet been established. We aimed to examine the risk of PE in patients with pemphigus. A large-scale population-based longitudinal cohort study was conducted to evaluate the relative risk (RR) of PE among 1,985 patients with pemphigus relative to 9,874 age-, sex-, and ethnicity-matched control subjects. A multivariate Cox regression model was utilized. The incidence of PE was 3.0 (95% CI, 2.2-4.0) and 1.2 (95% CI, 1.0-1.5) per 1,000 person-years among patients with pemphigus and controls, respectively. The period prevalence of PE corresponding to the study period was 2.2% (95% CI, 1.6-2.9%) among cases and 0.9% (95% CI, 0.7-1.1%) among controls. Patients with pemphigus were twice as likely to develop PE as compared to control subjects (adjusted RR, 1.98; 95% confidence interval [CI], 1.29-3.04). The highest PE risk was observed during the 1st year following the diagnosis of pemphigus (adjusted RR, 3.55; 95% CI, 1.78-7.09) and decreased over time. The increased risk was robust to a sensitivity analysis that included only cases managed by pemphigus-related systemic medications (adjusted RR, 1.82; 95% CI, 1.11-2.98). In conclusion, pemphigus is associated with an increased risk of PE, particularly during the 1st year of the disease. An awareness of this risk should be increased, additional precipitating factors for PE should be avoided, and thromboprophylaxis may be evaluated in high-risk patients. Further research is required to establish this risk.

Keywords: epidemiology; pemphigus; pulmonary embolism; risk; thromboprophilaxis.

References

    1. Willich SN, Chuang L-H, van Hout B, Gumbs P, Jimenez D, Kroep S, et al. . Pulmonary embolism in Europe - burden of illness in relationship to healthcare resource utilization and return to work. Thromb Res. (2018) 170:181–91. 10.1016/j.thromres.2018.02.009
    1. Goldhaber SZ, Visani L, De Rosa M. Acute pulmonary embolism: clinical outcomes in the international cooperative pulmonary embolism registry (ICOPER)[see comment]. Lancet. (1999) 353:1386–9. 10.1016/S0140-6736(98)07534-5
    1. Bergmann JF, Lloret-Linares C, Rami A, Cohen AT, Garay RP, Kakkar AK, et al. . Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study. Lancet. (2008) 371:387–94. 10.1016/S0140-6736(08)60202-0
    1. Xu J, Lupu F, Esmon CT. Inflammation, innate immunity and blood coagulation. Hamostaseologie. (2010) 30:5–6. 10.1055/s-0037-1617146
    1. Zöller B, Li X, Sundquist J, Sundquist K. Risk of pulmonary embolism in patients with autoimmune disorders: a nationwide follow-up study from Sweden. Lancet. (2012) 379:244–9. 10.1016/S0140-6736(11)61306-8
    1. Heit JA, Michael O'Fallon W, Petterson TM, Lohse CM, Silverstein MD, Mohr DN, et al. . Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population-based study. Arch Intern Med. (2002) 162:1245–8. 10.1001/archinte.162.11.1245
    1. Rennert G, Peterburg Y. Prevalence of selected chronic diseases in Israel. Isr Med Assoc J. (2001) 3:404–8.
    1. Holmqvist ME, Neovius M, Eriksson J, Mantel Ä, Wållberg-Jonsson S, Jacobsson LTH, et al. . Risk of venous thromboembolism in patients with rheumatoid arthritis and association with disease duration and hospitalization. JAMA. (2012) 308:1350–6. 10.1001/2012.jama.11741
    1. Mok CC, Tang SSK, To CH, Petri M. Incidence and risk factors of thromboembolism in systemic lupus erythematosus: a comparison of three ethnic groups. Arthritis Rheum. (2005) 52:2774–82. 10.1002/art.21224
    1. Stein PD, Goldman J, Matta F, Yaekoub AY. Diabetes mellitus and risk of venous thromboembolism. Am J Med Sci. (2009) 337:259–64. 10.1097/MAJ.0b013e31818bbb8b
    1. Grainge MJ, West J, Card TR. Venous thromboembolism during active disease and remission in inflammatory bowel disease: a cohort study. Lancet. (2010) 375:657–63. 10.1016/S0739-5930(10)79465-4
    1. Borjas-Howard J, Leeuw K, Rutgers A, Meijer K, Tichelaar V. Risk of recurrent venous thromboembolism in autoimmune diseases: a systematic review of the literature. Semin Thromb Hemost. (2018) 45:141–9. 10.1055/s-0038-1661387
    1. Ludvigsson JF, Welander A, Lassila R, Ekbom A, Montgomery SM. Risk of thromboembolism in 14,000 individuals with coeliac disease. Br J Haematol. (2007) 39:121–7. 10.1111/j.1365-2141.2007.06766.x
    1. Merkel PA, Lo GH, Holbrook JT, Tibbs AK, Allen NB, Davis JC, et al. . Brief communication: High incidence of venous thrombotic events among patients with Wegener granulomatosis - the Wegener's clinical occurrence of thrombosis (WeCLOT) study. Ann Intern Med. (2005) 142:620–6. 10.7326/0003-4819-142-8-200504190-00010
    1. Leshem YA, Atzmony L, Dudkiewicz I, Hodak E, Mimouni D. Venous thromboembolism in patients with pemphigus: a cohort study. J Am Acad Dermatol. (2017) 77:256–60. 10.1016/j.jaad.2017.01.059
    1. Ramagopalan SV, Wotton CJ, Handel AE, Yeates D, Goldacre MJ. Risk of venous thromboembolism in people admitted to hospital with selected immune-mediated diseases: Record-linkage study. BMC Med. (2011) 9:1. 10.1186/1741-7015-9-1
    1. Cugno M, Tedeschi A, Borghi A, Bucciarelli P, Asero R, Venegoni L, et al. . Activation of blood coagulation in two prototypic autoimmune skin diseases: a possible link with thrombotic risk. PLoS ONE. (2015) 10:e0129456. 10.1371/journal.pone.0129456
    1. Marzano A V, Tedeschi A, Spinelli D, Fanoni D, Crosti C, Cugno M. Coagulation activation in autoimmune bullous diseases. Clin Exp Immunol. (2009) 158:31–6. 10.1111/j.1365-2249.2009.03989.x
    1. Stuijver DJF, Majoor CJ, Van Zaane B, Souverein PC, De Boer A, Dekkers OM, et al. . Use of oral glucocorticoids and the risk of pulmonary embolism: A population-based case-control study. Chest. (2013) 143:1337–42. 10.1378/chest.12-1446
    1. Heit JA, Silverstein MD, Mohr DN, Petterson TM, O'Fallon WM, Melton LJ. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med. (2000) 160:809–15. 10.1001/archinte.160.6.809
    1. Kridin K, Zelber-Sagi S, Khamaisi M, Cohen AD, Bergman R. Remarkable differences in the epidemiology of pemphigus among two ethnic populations in the same geographic region. J Am Acad Dermatol. (2016) 75:925–30. 10.1016/j.jaad.2016.06.055
    1. Hsu D, Brieva J, Silverberg JI. Costs of care for hospitalization for pemphigus in the United States. JAMA Dermatol. (2016) 152:645. 10.1001/jamadermatol.2015.5240
    1. Ren Z, Narla S, Hsu DY, Silverberg JI. Association of serious infections with pemphigus and pemphigoid: analysis of the nationwide inpatient sample. J Eur Acad Dermatology Venereol. (2018) 32:1768–76. 10.1111/jdv.14961
    1. Alikhan R, Cohen AT, Combe S, Samama MM, Desjardins L, Eldor A, et al. . Risk factors for venous thromboembolism in hospitalized patients with acute medical illness: analysis of the MEDENOX study. Arch Intern Med. (2004) 164:963–8. 10.1001/archinte.164.9.963
    1. Barbar S, Noventa F, Rossetto V, Ferrari A, Brandolin B, Perlati M, et al. . A risk assessment model for the identification of hospitalized medical patients at risk for venous thromboembolism: the padua prediction score. J Thromb Haemost. (2010) 8:2450–7. 10.1111/j.1538-7836.2010.04044.x
    1. Birkenfeld S, Dreiher J, Weitzman D, Cohen AD. Coeliac disease associated with psoriasis. Br J Dermatol. (2009) 161:1331–4. 10.1111/j.1365-2133.2009.09398.x

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit